131 related articles for article (PubMed ID: 37848556)
1. Predictors of outcomes in hematopoietic cell transplantation for Fanconi anemia.
Cancio M; Troullioud Lucas AG; Bierings M; Klein E; de Witte MA; Smiers FJ; Bresters D; Boelens JJ; Smetsers SE
Bone Marrow Transplant; 2024 Jan; 59(1):34-40. PubMed ID: 37848556
[TBL] [Abstract][Full Text] [Related]
2. T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML.
Satty AM; Klein E; Mauguen A; Kunvarjee B; Boelens JJ; Cancio M; Curran KJ; Kernan NA; Prockop SE; Scaradavou A; Spitzer B; Tamari R; Ruggiero J; Torok-Castanza J; Mehta PA; O'Reilly RJ; Boulad F
Bone Marrow Transplant; 2024 Jan; 59(1):23-33. PubMed ID: 37773270
[TBL] [Abstract][Full Text] [Related]
3. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
[TBL] [Abstract][Full Text] [Related]
4. Does Mixed Chimerism After Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients With Fanconi Anemia Impact on Outcome?
Ayas M; Siddiqui K; Al-Jefri A; Al-Ahmari A; Ghemlas I; Al-Saedi H; Al-Anazi A; Khan S; El-Solh H; Al-Seraihi A
Transplant Cell Ther; 2021 Mar; 27(3):257.e1-257.e6. PubMed ID: 33781527
[TBL] [Abstract][Full Text] [Related]
5. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
6. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
7. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
Tan PL; Wagner JE; Auerbach AD; Defor TE; Slungaard A; Macmillan ML
Pediatr Blood Cancer; 2006 May; 46(5):630-6. PubMed ID: 16078221
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.
Ayas M; Saber W; Davies SM; Harris RE; Hale GA; Socie G; LeRademacher J; Thakar M; Deeg HJ; Al-Seraihy A; Battiwalla M; Camitta BM; Olsson R; Bajwa RS; Bonfim CM; Pasquini R; Macmillan ML; George B; Copelan EA; Wirk B; Al Jefri A; Fasth AL; Guinan EC; Horn BN; Lewis VA; Slavin S; Stepensky P; Bierings M; Gale RP
J Clin Oncol; 2013 May; 31(13):1669-76. PubMed ID: 23547077
[TBL] [Abstract][Full Text] [Related]
9. Haplo-identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT.
Zubicaray J; Pagliara D; Sevilla J; Eikema DJ; Bosman P; Ayas M; Zecca M; Yesilipek A; Kansoy S; Renard C; Dalle JH; Campos A; Faraci M; Kupesiz A; Smiers FJW; Velardi A; Abecasis M; Corti P; Fagioli F; González Muñiz S; Kriván G; Dufour C; Risitano A; Corbacioglu S; Peffault de Latour R
Am J Hematol; 2021 May; 96(5):571-579. PubMed ID: 33606297
[TBL] [Abstract][Full Text] [Related]
10. Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.
Xu L; Lu Y; Hu S; Li C; Tang Y; Wang H; Yan J; Chen J; Liu S; Sun Y; Wu X; Lin F; Lu P; Huang X;
Br J Haematol; 2022 Nov; 199(3):401-410. PubMed ID: 35989315
[TBL] [Abstract][Full Text] [Related]
11. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
12. Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia.
Ebens CL; DeFor TE; Tryon R; Wagner JE; MacMillan ML
Biol Blood Marrow Transplant; 2018 Apr; 24(4):765-771. PubMed ID: 29203412
[TBL] [Abstract][Full Text] [Related]
13. Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation.
van Roessel I; Prockop S; Klein E; Boulad F; Scaradavou A; Spitzer B; Kung A; Curran K; O'Reilly RJ; Kernan NA; Cancio M; Boelens JJ
Cytotherapy; 2020 Sep; 22(9):503-510. PubMed ID: 32622752
[TBL] [Abstract][Full Text] [Related]
14. Successful Outcome in Patients with Fanconi Anemia Undergoing T Cell-Replete Mismatched Related Donor Hematopoietic Cell Transplantation Using Reduced-Dose Cyclophosphamide Post-Transplantation.
Ayas M; Siddiqui K; Al-Jefri A; Al-Ahmari A; Ghemlas I; Al-Saedi H; Alanazi A; Jafri R; Ayas MF; Al-Seraihi A
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2217-2221. PubMed ID: 31306778
[TBL] [Abstract][Full Text] [Related]
15. Survival and toxicity outcomes of hematopoietic stem cell transplantation for pediatric patients with Fanconi anemia: a unified multicentric national study from the Spanish Working Group for Bone Marrow Transplantation in Children.
Murillo-Sanjuán L; González-Vicent M; Argilés Aparicio B; Badell Serra I; Rodríguez Villa A; Uria Oficialdegui ML; López-Duarte M; Beléndez-Bieler C; Sastre Urgelles A; Sevilla Navarro J; Diaz-de-Heredia C;
Bone Marrow Transplant; 2021 May; 56(5):1213-1216. PubMed ID: 33303901
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
17. Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.
Ayas M; Eapen M; Le-Rademacher J; Carreras J; Abdel-Azim H; Alter BP; Anderlini P; Battiwalla M; Bierings M; Buchbinder DK; Bonfim C; Camitta BM; Fasth AL; Gale RP; Lee MA; Lund TC; Myers KC; Olsson RF; Page KM; Prestidge TD; Radhi M; Shah AJ; Schultz KR; Wirk B; Wagner JE; Deeg HJ
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1790-5. PubMed ID: 26116087
[TBL] [Abstract][Full Text] [Related]
18. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
Mehta PA; Davies SM; Leemhuis T; Myers K; Kernan NA; Prockop SE; Scaradavou A; O'Reilly RJ; Williams DA; Lehmann L; Guinan E; Margolis D; Baker KS; Lane A; Boulad F
Blood; 2017 Apr; 129(16):2308-2315. PubMed ID: 28179273
[TBL] [Abstract][Full Text] [Related]
19. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Truscott L; Pariury H; Hanmod S; Davini M; de la Maza M; Sapp LN; Staples K; Proytcheva M; Katsanis E
Pediatr Blood Cancer; 2023 Feb; 70(2):e30102. PubMed ID: 36394072
[TBL] [Abstract][Full Text] [Related]
20. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
